elEconomista

Baxter´s Low Glucose PD Solutions Favorably Impacted Metabolic Measures Including Glycemic Control in Trials of Diabetics Undergoing Dialysis

Combining both studies, the IMPENDIA/EDEN trials randomized 124 patients to a low glucose PD regimen containing either PHYSIONEAL (glucose), EXTRANEAL (icodextrin 7.5%), and NUTRINEAL (PD4 1.1% amino ...
Medscape

FDA Safety Changes: Exjade and Extraneal

This activity is part of an ongoing CME/CE initiative to provide information on labeling changes reported by the FDA. Activities of this nature will be posted on Medscape on a weekly basis. June 10, ...
Pharmabiz

First solution with new class of osmotic agent in United States

Baxter Healthcare Corporation announced that the U.S. Food and Drug Administration (FDA) has approved Extraneal (icodextrin), a peritoneal dialysis (PD) solution. This solution offers the potential ...
Nature

Use of icodextrin for peritoneal dialysis can lead to false diagnosis of hyperglycemia

The iso-osmotic peritoneal dialysis solution icodextrin (Extraneal ®, Baxter International, Inc., Deerfield, IL) contains glucose polysaccharides, which are hydrolyzed by α-amylase to maltose, ...